A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer

Inclusion Criteria: * Ability to understand and willingness to sign a written informed consent document. * Age ≥18 years. * Newly diagnosed have histologically or cytologically proven adenocarcinoma of the pancreas. * Tumor must be resectable. * Patient's acceptance to have a tumor biopsy. * ECOG performance status 0 or 1 * Patients must have adequate organ and marrow function defined by study-specified laboratory tests. * For both Women and Men, must use acceptable form of birth control while on study. Exclusion Criteria: * Have received any anti-pancreatic cancer therapy. * Have been diagnosed with another malignancy whose natural history or treatment has the potential to interfere with safety or efficacy assessment of this study. * Conditions, including alcohol or drug dependence, intercurrent illness, or lack of sufficient peripheral venous access, that would affect the patient's ability to comply with study visits and procedures * Subjects with active, known or suspected autoimmune disease that may relapse. * Systemic steroid therapy (\> 10mg daily prednisone equivalent) or immunosuppressive therapy within 14 days of first dose of study drug administration. * Active infection requiring systemic therapy. * Infection with HIV or hepatitis B or C at screening• * History of interstitial lung disease, non-infectious pneumonitis or uncontrolled diseases including pulmonary fibrosis, acute lung diseases, etc. * Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, pulmonary embolism, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, metastatic cancer, or psychiatric illness/social situations that would limit compliance with study requirements. * Prior allogeneic stem cell transplantation or organ transplantation * Any major surgical procedure requiring general anesthesia ≤ 28 days before first dose of study drug. * Have received a live vaccine ≤ 28 days before first dose of study drug. * Use of QT prolonging drugs within 2 weeks before the start of SX-682 dosing and for the length of the study. * ECG demonstrating a QTc interval ≥ 470 msec or patients with congenital long QT syndrome. * Severe hypersensitivity reaction to any monoclonal antibody. * Concurrent participation in another therapeutic clinical study * Pregnant or breastfeeding